What are the effects of regional differences in Asia on the efficacy and safety of Edoxaban compared to Warfarin?
Shimada et al. (2015) found that in patients with atrial fibrillation, using Edoxaban compared to Warfarin resulted in improved efficacy and safety in different regions of Asia. They found that Edoxaban was associated with lower rates of stroke or systemic embolism, major bleeding and all-cause mortality, compared to Warfarin. Additionally, Edoxaban was also found to have improved time in therapeutic range (TTR) compared to Warfarin, and it was associated with lower rates of clinically relevant non-major bleeding. Furthermore, Edoxaban was also found to be associated with lower rates of net adverse clinical events (NACE) compared to Warfarin. Thus, the study concluded that Edoxaban is an effective and safe anticoagulant compared to Warfarin, with improved efficacy and safety across different regions in Asia. 